Grants for Special District Governments

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage current NCI R01 research projects to incorporate new technologies from the NCI Innovative Molecular Analysis Technologies program, with the goal of enhancing their original research and speeding up scientific discoveries in cancer research.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage existing NCI P50 specialized centers to enhance their current cancer research by integrating new technologies or methods developed by the NCI Innovative Molecular Analysis Technologies program.

This funding opportunity provides financial support to individuals, organizations, and businesses looking to improve the community of Rancho Cordova through various projects and programs.

This funding is designed to assist Rockland County in providing essential services and support to individuals and families facing homelessness or housing instability, helping them secure permanent housing and regain stability.

The "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research" grant aims to fund the development of innovative technologies that enhance the quality of biological samples used in cancer research, by addressing issues related to sample degradation during collection, processing, and storage, and by establishing quality control measures.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage current NCI U01 research projects to incorporate new technologies from the NCI Innovative Molecular Analysis Technologies program, in order to enhance their original research and speed up scientific discoveries in cancer research.

This grant provides funding to non-profit organizations, schools, and government entities that serve the residents of Henry County in areas such as health, education, social services, cultural affairs, and civic affairs.

This grant provides funding to local governments in Mississippi to develop or improve public boating access facilities on lakes and rivers.

This funding opportunity supports nonprofits, researchers, local governments, and small businesses in Virginia to enhance recreational fishing through conservation, habitat restoration, and fisheries research.

This program provides financial assistance to local governments in Virginia's Tobacco Region to attract and expand businesses that create jobs and invest in the local economy.

This fund provides financial support to nonprofit organizations that help meet basic human needs and improve access to education and safe recreational activities for marginalized groups, particularly children, seniors, and individuals with special needs, especially in the wake of the pandemic.

This program provides federal funds to non-profits and local organizations to improve housing, economic opportunities, and living conditions for low- and moderate-income residents in Federal Way.

This state-funded program provides financial support to small cities, counties, and tribal communities in Idaho for infrastructure and economic development projects that promote job creation and growth in rural areas.

The U.S. Food and Drug Administration (FDA) seeks applications to develop, implement, and evaluate a human abuse potential (HAP) study of botanical Kratom. FDA has previously warned consumers about the use of Kratom (Mitragyna speciosa), a plant indigenous to Southeast Asia. Kratom alkaloids have demonstrated both affinity and activity at receptor sites known to be associated with abuse, such as mu opioid receptors. Although Kratom use is prevalent, to date, clinical evaluations of its abuse potential have been limited. The proposed HAP study should be performed in accordance with the guidance for industry, "Assessment of Abuse Potential of Drugs," including (but not limited to) the selection of an appropriate comparator(s) and outcome measures, statistical analyses etc. Interested parties, will also complete the submission of an Investigational New Drug (IND) application and obtain Institutional Review Board (IRB) clearance.

This grant provides funding for future projects that benefit organizations serving Lapeer County, Michigan, including non-profits, educational institutions, and government entities.

This funding opportunity provides additional financial support to researchers with existing NIH grants to expand their projects and address new scientific challenges or opportunities.

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.

The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereo chemically controlled synthesis and biological activity assessment using in vitro and animal models. The proposed studies will focus on 1) synthesis of each diastereomer of LEQVIO (Inclisiran) in stereo chemically pure form; 2) assessment of the biological activity of each stereo chemically pure diastereomer in inhibiting PCSK9 activity using in vitro assays and in a transgenic mouse model; 3) development of analytical methods to identify and characterize the stereochemical structure of each diastereomer in LEQVIO; and 4) assessment of the individual contribution of each diastereomer to the overall pharmacological activity of LEQVIO. Tools developed in this research can also be applied to other similar GalNAc-conjugated siRNAs specifically, and other siRNAs in general. Knowledge gained from this research will also contribute to the sameness evaluation of generic siRNAs, and to the quality control of oligonucleotide drugs.

The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement. The proposed work directly supports the U.S. FDAs stated goal of protecting public health from unacceptable risks from nitrosamine impurities in human drugs. Although significant experimental and policy/regulatory initiatives have been undertaken in this area, there remains a need for further research into and development and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The aim is to improve the safety of human drugs with potential nitrosamine impurity liabilities. In addition to the work outlined above, the award recipient will assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends.

The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.